Key Takeaway: Precision BioSciences, Inc. will present at the 31st Annual Congress of the European Society of Gene & Cell Therapy. The company is known for its proprietary ARCUS platform, which is designed for advanced gene editing therapies, including gene insertion. This presentation highlights the company's commitment to innovative gene editing solutions.
Price reaction · baseline $6.5 (2024-11-21 close) · hit pre-market · 8 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
+11.7%
day 1
+11.4%
day 3
+9.4%
Market Sentiment Analysis
POSITIVE FACTORS
Precision BioSciences is presenting at a significant industry event.
The company is utilizing its proprietary ARCUS platform for gene editing.
Focus on in vivo gene editing therapies indicates innovative approaches.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
DURHAM, N.C. –(BUSINESS WIRE)–Oct. 16, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL) is an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion which is necessary for
Frequently Asked Questions
What is the focus of Precision BioSciences' presentation?
The presentation will focus on their ARCUS platform for in vivo gene editing therapies.
When is the ESGCT 31st Annual Congress?
The ESGCT 31st Annual Congress is scheduled for October 2024.
What technology does Precision BioSciences use?
Precision BioSciences utilizes its proprietary ARCUS platform for gene editing.
Where is Precision BioSciences based?
Precision BioSciences is based in Durham, North Carolina.